HPV vaccine

Merck Surges on Vaccine Hopes, Analyst Optimism

Merck shares rose more than 6% in two days as investors reacted to an analyst's upgrade and news that the drugmaker is trying to broaden the market for its human papillomavirus/cervical cancer vaccine, Gardasil.